Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
Public ClinicalTrials.gov record NCT04972487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Global Early Access Program to Provide Tofersen To Patients With Amyotrophic Lateral Sclerosis (ALS) Associated With a Mutation in the Superoxide Dismutase 1 (SOD1) Gene
Study identification
- NCT ID
- NCT04972487
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- Biogen
- Industry
- Enrollment
- Not listed
Conditions and interventions
Interventions
- Tofersen Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jun 9, 2024
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anchorage | Alaska | 99508 | — |
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | San Diego | California | 92103 | — |
| Research Site | San Francisco | California | 94114 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Worcester | Massachusetts | 01655 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Lebanon | New Hampshire | 03766 | — |
| Research Site | Amherst | New York | 14226 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Syracuse | New York | 13210 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Austin | Texas | 78759 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04972487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2024 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04972487 live on ClinicalTrials.gov.